Cloughesy, T. F., Bent, M. J. V. D., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J. L., Mendez, J. S., Welsh, L., Mason, W. P., Hottinger, A. F., Sepúlveda, J. M., Wick, W., Soffietti, R., Zhao, D., Jimenez, J., Dominguez, E. E., Hassan, I., Wen, P. Y., Mellinghoff, I. K. (2026). A global, randomized, double-blinded, phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an
                    <i>IDH1/2</i>
                    mutation (INDIGO): Updated efficacy and safety.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.2010